Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurocritical Care
Erschienen in: Neurocritical Care 2/2012

01.04.2012 | Review Article

Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis

verfasst von: Frances Caprio, Richard A. Bernstein

Erschienen in: Neurocritical Care | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Cerebral venous sinus thrombosis (CVST) often occurs in young patients and is treated with acute and then long-term oral anticoagulation. It is important to decide when to discontinue anticoagulation, as lifelong anticoagulation exposes the patient to considerable cumulative risk. However, a lack of high quality studies makes choosing a duration of anticoagulation after CVST difficult. In this article, we review the evidence for different treatment durations in several common clinical scenarios of CVST. In addition, when no direct evidence is available, we discuss and extrapolate from the more comprehensively studied situation of systemic venous thromboembolic disease. Recommendations are graded using standard criteria for the level of evidence.
Literatur
1.
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, de Veber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158–92.PubMedCrossRef
2.
Stam J, de Bruijn SF, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;(4):CD002005.
3.
Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597–600.PubMedCrossRef
4.
de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484–8.PubMedCrossRef
5.
Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis: follow-up of 77 patients. Stroke. 1996;27:243–6.PubMedCrossRef
6.
Brucker AB, Vollert-Rogenhofer H, Wagner M, Stieglbauer K, Felber S, Trenkler J, Deisenhammer E, Aichner F. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis. 1998;8:331–7.PubMedCrossRef
7.
Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87–111.PubMed
8.
Strupp M, Covi M, Seelos K, Dichgans M, Brandt T. Cerebral venous thrombosis: correlation between recanalization and clinical outcome: a long-term follow-up of 40 patients. J Neurol. 2002;249:1123–4.PubMedCrossRef
9.
Stolz E, Trittmacher S, Rahimi A, Gerriets T, Röttger C, Siekmann R, Kaps M. Influence of recanalization on outcome in dural sinus thrombosis: a prospective study. Stroke. 2004;35:544–7.PubMedCrossRef
10.
Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry. 2003;74:459–61.PubMedCrossRef
11.
Röttger C, Trittmacher S, Gerriets T, Blaes F, Kaps M, Stolz E. Reversible MR imaging abnormalities following cerebral venous thrombosis. AJNR Am J Neuroradiol. 2005;26:607–13.PubMed
12.
Nagaraja D, Rao BSS, Taly AB. Randomized controlled trial of heparin in therapy of cerebral venous/sinus thrombosis. Nimhans J. 1995;13:111–5.
13.
Ferro JM, Canhão P, Stam J, Bousser MG. Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMedCrossRef
14.
Ferro JM, Correia M, Pontes C, Baptista MV, Pita F. Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis. 2001;11:177–82.PubMedCrossRef
15.
Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M. Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome. Clin Neurol Neurosurg. 2005;107:99–107.PubMedCrossRef
16.
Girot M, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Leys D. ISCVT investigators. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke. 2007;38:337–42.PubMedCrossRef
17.
Masuhr F, Mehraein S, Einhäupl K. Cerebral venous and sinous thrombosis. J Neurol. 2004;251:11–23.PubMedCrossRef
18.
Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J. Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis: results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272–8.PubMedCrossRef
19.
Maqueda VM, Thijs V. Risk of thromboembolism after cerebral venous thrombosis. Eur J Neurol. 2006;13:302–5.PubMedCrossRef
20.
Gosk-Bierska I, Wysokinski W, Brown RD Jr, Karnicki K, Grill D, Wiste H, Wysokinska E, McBane RD 2nd. Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology. 2006;67:814–9.PubMedCrossRef
21.
Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010;121:2740–6.PubMedCrossRef
22.
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) [published correction appears in Chest 2008;134:892]. Chest. 2008;133(6 suppl):454S–545S.
23.
Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340:873–6.
24.
Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606–11.PubMed
25.
Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661–5.PubMedCrossRef
26.
Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453–60.PubMed
27.
Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med. 2001;345:165–9.PubMedCrossRef
28.
Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19–25.PubMed
29.
Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomized trial. BMJ. 2007;334:674–80.PubMedCrossRef
30.
Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7. (LAFIT).PubMedCrossRef
31.
Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–34. (PREVENT).PubMedCrossRef
32.
Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393–8. (DURAC 2).PubMedCrossRef
33.
Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780–9. (PROLONG).PubMedCrossRef
34.
Cosmi B, Legnani C, Tosetto A, et al. Use of Ddimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis. 2009;28:381e8.CrossRef
35.
Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706e15.
36.
Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.PubMedCrossRef
37.
Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl):257S–98S.PubMedCrossRef
38.
Kearon C. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy. Clin Chest Med. 2010;31(4):719–30.PubMedCrossRef
39.
Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–6.PubMedCrossRef
40.
Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.PubMedCrossRef
41.
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):381S–453S.PubMedCrossRef
42.
Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523–6.PubMedCrossRef
43.
Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352–61.PubMedCrossRef
44.
Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14–7.PubMed
45.
Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden. Thromb Haemost. 1997;77:624–8.PubMed
46.
Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166:729–36.PubMedCrossRef
47.
Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A Allele in the coagulation factor V gene and the G20210A Allele in the prothrombin gene. Thromb Haemost. 1999;81:684–9.PubMed
48.
Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001;37:215–8.PubMedCrossRef
49.
Palareti G, Legnani C, Cosmi B, et al. Predictive value of d-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313–8.PubMedCrossRef
50.
Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800–2.PubMed
51.
Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329–33.PubMed
52.
Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med. 1998;158:1369.PubMed
53.
Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143:321.PubMedCrossRef
54.
Coppens M, Reijnders JH, Middeldorp S, et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost. 2008;6:1474.PubMedCrossRef
55.
Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol. 1997;34:256.PubMed
56.
Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 2012A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426.PubMed
57.
Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002;116:625.PubMedCrossRef
58.
Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamulyák K, Prins MH, Büller HR, van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.PubMedCrossRef
59.
de Freitas GR, Bogousslavsky J. Risk factors of cerebral vein and sinus thrombosis. Front Neurol Neurosci. 2008;23:23–54.PubMed
60.
Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793–7.PubMedCrossRef
61.
Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126–32.PubMedCrossRef
62.
Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006;107:2766–73.PubMedCrossRef
63.
Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Jüttler E, Druschky KF, Patscheke H. Prothrombin gene G202103A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29:1765–9.PubMedCrossRef
64.
Einhäupl K, Stam J, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17:1229–35.PubMedCrossRef
65.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRef
66.
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y, Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.PubMedCrossRef
67.
Schulman S, Svenungsson E, Granqvist S, Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–8.PubMedCrossRef
68.
Gadelha T, André C, Jucá AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19:49–52.PubMedCrossRef
69.
Bergendal A, Odlind V, Persson I, Kieler H. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand. 2009;88(3):261–6.PubMedCrossRef
70.
Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res. 2011;127(Suppl 3):S30–4.PubMedCrossRef
71.
Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644–91.PubMedCrossRef
72.
73.
Wilterdink JL, Easton JD. Cerebral ischemia in pregnancy. Adv Neurol. 2002;90:51–62.PubMed
74.
Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke. 2000;31:1274–82.PubMedCrossRef
75.
James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol. 2005;106:509–16.PubMedCrossRef
76.
Françcois P, Fabre M, Lioret E, Jan M. Vascular cerebral thrombosis during pregnancy and post-partum. Neurochirurgie. 2000;46:105–9.
77.
Lanska DJ, Kryscio RJ. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997;89:413–8.PubMedCrossRef
78.
Bates S, Greer I, Pabinger I, Sofaer S, Hirsch J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:844S–86S.PubMedCrossRef
79.
Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002;100:1060–2.PubMedCrossRef
80.
Lamy C, Hamon JB, Coste J, Mas JL, French Study Group on Stroke in Pregnancy. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. Neurology. 2000;55:269–74.PubMed
81.
Mehraein S, Ortwein H, Busch M, Weih M, Einhäupl K, Masuhr F. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry. 2003;74:814–6.PubMedCrossRef
82.
Srinivasan K. Cerebral venous and arterial thrombosis in pregnancy and puerperium: a study of 135 patients. Angiology. 1983;34:731–46.PubMedCrossRef
Metadaten
Titel
Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis
verfasst von
Frances Caprio
Richard A. Bernstein
Publikationsdatum
01.04.2012
Verlag
Humana Press Inc
Erschienen in
Neurocritical Care / Ausgabe 2/2012
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-011-9661-1

Weitere Artikel der Ausgabe 2/2012

Neurocritical Care 2/2012 Zur Ausgabe

Practical Pearl

Early Ketamine to Treat Refractory Status Epilepticus

Original Article

Head Computed Tomography Scanning During Pediatric Neurocritical Care: Diagnostic Yield and the Utility of Portable Studies

Original Article

Critical Thresholds for Cerebrovascular Reactivity After Traumatic Brain Injury

Original Article

Potassium Sparing Diuretics as Adjunct to Mannitol Therapy in Neurocritical Care Patients with Cerebral Edema: Effects on Potassium Homeostasis and Cardiac Arrhythmias

Original Article

Circadian Variation in Ictus of Aneurysmal Subarachnoid Hemorrhage

Translational Research

The apoE-mimetic Peptide, COG1410, Improves Functional Recovery in a Murine Model of Intracerebral Hemorrhage

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise